1M.D. Ankara Training and Research Hospital, Eye Clinic, Ankara/TURKEY 2M.D. Associate Professor, Ankara Training and Research Hospital, Eye Clinic, Ankara/TURKEY 3M.D. Associate Professor, Yıldırım Bayazıt University Faculty of Medicine, Department of Ophthalmology, Ankara/TURKEY 4M.D. Professor, Ankara Training and Research Hospital, Eye Clinic, Ankara/TURKEY
Purpose: To evaluate the effect of initial central foveal thickness (CFT) on the anatomical and visual prognosis on intravitreal ranibizumab
treatment for diabetic macular edema (DME).
Materials and Methods: Patients received intravitreal ranibizumab treatment for DME and having follow-up at least 6 months were evaluated.
The demographic features, the CFT and best corrected visual acuity (BCVA) initially, at 3 month, at 6 month and at last follow up was recorded.
The cases having CFT less than 400 μm (group 1) and having CFT 400 μm and more (group 2) were compared according to anatomical and
Results: The mean follow up period of 35 eyes in group 1 and 47 eyes in group 2 was 16.49±7.58 months. The CFT initially, at 3 month, at 6
month and at last follow up in group 1 was 345.06±44.38 μm, 299.14±78.8 μm, 315.83±98.6 μm, 277.47±85 μm and in group 2, 510.23±85.16
μm, 368.64±138.4 μm, 380.30±145.1 μm and 322.23±134.15 mm respectively. There was no statistical significant difference between groups
at last follow up. The BCVA initially, at 3 month, at 6 month and at last follow up in group 1 was 0.63±0.47 logMar, 0.5±0.5 logMar, 0.38±0.43
logMar, 0.36±0.48 logMar and in group 2, 0.72±0.4 logMar, 0.58±0.5 logMar, 0.58±0.5 logMar and 0.55±0.42 logMar respectively. The difference
between groups at last follow up was statistical significant.
Conclusion: The beginning CFT may be a factor affecting adversely the visual prognosis. In cases with high macular thickness, successful
anatomic results can be obtained.